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Relapsing experimental autoimmune encephalomyelitis (R-EAE) in the SJL mouse is a Th1-mediated
autoimmune demyelinating disease model for human multiple sclerosis and is characterized by infiltration of the central nervous system (CNS) by Th1 cells and macrophages. Disease relapses are mediated by
T cells specific for endogenous myelin epitopes released during acute disease, reflecting a critical role for
epitope spreading in the perpetuation of chronic central CNS pathology. We asked whether blockade of
the CD40–CD154 (CD40L) costimulatory pathway could suppress relapses in mice with established REAE. Anti-CD154 antibody treatment at either the peak of acute disease or during remission effectively
blocked clinical disease progression and CNS inflammation. This treatment blocked Th1 differentiation
and effector function rather than expansion of myelin-specific T cells. Although T-cell proliferation and
production of interleukin (IL)-2, IL-4, IL-5, and IL-10 were normal, antibody treatment severely inhibited
interferon-γ production, myelin peptide–specific delayed-type hypersensitivity responses, and induction
of encephalitogenic effector cells. Anti-CD154 antibody treatment also impaired the expression of clinical disease in adoptive recipients of encephalitogenic T cells, suggesting that CD40–CD154 interactions
may be involved in directing the CNS migration of these cells and/or in their effector ability to activate
CNS macrophages/microglia. Thus, blockade of CD154–CD40 interactions is a promising immunotherapeutic strategy for treatment of ongoing T cell–mediated autoimmune diseases.
J. Clin. Invest. 103:281–290 (1999).

Introduction
Relapsing experimental autoimmune encephalomyelitis
(R-EAE) is a Th1-mediated autoimmune demyelinating
disease of the central nervous system (CNS), that serves
as a useful model for multiple sclerosis (MS) (1). Induction of R-EAE in the susceptible SJL mouse strain by subcutaneous inoculation with the major immunodominant epitope of proteolipid protein (PLP139-151) in
complete Freund’s adjuvant (CFA) or by the adoptive
transfer of PLP139-151–specific T cells results in a disease course characterized by a moderate to severe acute
paralytic phase followed by remission and the subsequent development of spontaneous relapses (2). Relapsing disease episodes are accompanied by the development of T-cell responses to noninducing epitopes on the
same or distinct myelin proteins secondary to acute CNS
damage, a phenomenon termed epitope spreading (3, 4).
In PLP139-151–induced R-EAE, the first clinical relapse
is mediated predominantly by T cells specific for a secondary PLP epitope, PLP178-191 (4–6).
Regulation of ongoing R-EAE in the SJL/J mouse has
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been achieved by several immunoregulatory approaches including peptide-specific tolerance and blockade of
costimulatory molecules involved in T-cell activation.
We and others have shown that induction of peptidespecific tolerance by the intravenous injection of peptide-pulsed, ethylene carbadiimide (ECDI)-fixed antigen-presenting cells (APCs) blocks both induction and
progression of R-EAE (7–9). This effect is mediated
largely through the induction of anergy owing to the
inability of the fixed APCs to express required costimulatory molecules necessary for effective T-cell induction (10). In support of the blockade of the B7/CD28
costimulatory pathway leading to antigen-specific
unresponsiveness, a variety of studies have shown that
direct interference with the B7/CD28 costimulatory
pathway is an effective means of preventing induction
of R-EAE (11, 12) and of treating ongoing disease (6,
13). In addition, the CD40–CD40L (CD154) ligand pair
has been shown to be important for experimental
autoimmune encephalomyelitis (EAE) induction (14),
and blockade of this interaction using anti-CD154
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antibody inhibits early events in disease initiation (15).
Blockade of CD154–CD40 interactions have also been
shown to prevent the induction of other autoimmune
models such as oophoritis (16), experimental autoimmune thyroiditis (17), lupus nephritis (18), collageninduced arthritis (19), and spontaneous autoimmune
diabetes (20), indicating the tremendous potential of
this immunoregulatory strategy in treating autoimmune disease. In addition, recent studies have demonstrated that blockade of this interaction also inhibits
atherogenesis in hyperlipidemic mice (21).
CD40–CD154 interactions play multifunctional roles in
the immune system. Although originally identified as a
constitutive B-cell antigen, CD40 is expressed by many
cells, including dendritic cells, macrophages, and astrocytes (22). CD154 (CD40L), the ligand for CD40, is transiently expressed primarily by activated CD4 T cells,
although recently it has been identified on a subpopulation of activated B cells (23, 24). CD154 is upregulated by
ligation of the T-cell receptor (TCR) and can be further
increased by costimulatory events (24). CD40 ligation leads
to the upregulation of the costimulatory molecules B7-1
(CD80) and B7-2 (CD86) on APCs, enhancing their ability
to activate naive T-cells (24, 25). CD40–CD154 interactions
are crucial for B cell activation and differentiation (24, 25)
and for production of interleukin-12 (IL-12) by APCs,
which biases CD4 T-cell responses toward Th1 (26).
While anti-CD154 has been shown to inhibit induction
of EAE, the more relevant clinical potential of anti-CD154
therapy in treating ongoing EAE has yet to be evaluated.
In this article, we evaluate the role of anti-CD154 in
inhibiting ongoing disease and investigate the mechanisms by which inhibition occurs. We show for the first
time that anti-CD154 treatment is an effective way of
treating an established CD4 Th1-mediated autoimmune
disease in that it rapidly ameliorated ongoing acute
PLP139-151–induced R-EAE and, more importantly,
inhibited expression of clinical relapses when administered during disease remission. Disease inhibition was
associated with a dramatic decrease in immune cell infiltrates into the CNS and little or no demyelination. AntiCD154 therapy led to decreased lymph node T-cell expansion, but its effect was primarily associated with a
dramatic inhibition of differentiation of Th1 responses to
both the initiating and relapse-associated PLP epitopes.

Methods
Mice. Female SJL mice 5–6 weeks old were obtained from Harlan Sprague Dawley Inc. (Indianapolis, Indiana, USA) and NCI
Laboratories (Frederick, Maryland, USA). Mice were housed
under barrier conditions, and paralyzed mice were afforded
easier access to food and water.
Peptides. PLP139-151 (HSLGKWLGHPDKF) and PLP178-191
(NTWTTCQSIAFPSK) were synthesized by the peptide facility
at the University of North Carolina at Chapel Hill. Amino acid
composition of these peptides was verified by mass spectrometry, and purity (>97%) was confirmed by mass spectroscopy at the
Michigan State University Biotechnology Center. PLP178-191
was insoluble in PBS and was dissolved in 0.035 M acetic acid.
In vivo antibody treatment. Anti-CD154 (MR-1) was produced in
ascites and purified by HPLC over a DEAE column. Normal
hamster serum was purchased from Harlan Bioproducts for Science Inc. (Indianapolis, Indiana, USA) or Caltag Laboratories Inc.
282
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(Burlingame, California, USA) and purified in the same manner.
Mice were treated three to four times with 200 µg of control hamster Ig or MR-1 antibody intraperitoneally in a total volume of
200 µl administered every other day starting at either time of peptide inoculation, peak of acute phase, or when mice had entered
remission from acute phase.
Induction of active and adoptive R-EAE. For actively induced REAE, mice were immunized subcutaneously with 100 µl of a CFA
emulsion containing 200 µg of Mycobacterium tuberculosis H37Ra
(Difco Laboratories, Detroit, Michigan, USA) and 50 µg of
PLP139-151 distributed over three sites on the lateral hind flanks
and dorsally. For adoptive transfer of R-EAE, female donor SJL/J
mice (6–8 weeks old) were primed subcutaneously with 100 µg
of PLP139-151 in CFA distributed over four dorsal sites. Some
mice received 250 µg MR1 intraperitoneally on days 0, 2, 4, and
6. Draining lymph nodes (axillary and inguinal) were harvested
on day 8 and cultured in vitro in 24-well plates (8.0 × 106
cells/well) with supplemented Roswell Park Memorial Institute
medium (RPMI) (Sigma Chemical Co., St. Louis, Missouri, USA)
and 70 µg/ml PLP. MR-1 (25 µg/ml) was added to some of the in
vitro cultures. After 4 days in culture, the cells were harvested and
centrifuged over a Ficoll gradient to remove debris. Recipient
female SJL/J mice were intravenously injected with 1.25 × 106, 2.5
× 106, or 5.0 × 106 cells in a final volume of 500 µl. Donors and
recipients that were treated with anti-CD154 were given 250 µg
intraperitoneally three times a week.
Clinical evaluation. Mice were evaluated daily for clinical signs
of disease for up to 40 days after inoculation. Clinical severity
was assessed on a 0–5 scale as follows: grade 1, limp tail; grade
2, limp tail and hindlimb weakness (waddling gait); grade 3,
partial hindlimb paralysis; grade 4, complete hindlimb paralysis; and grade 5, moribund. The data are plotted as the daily
mean clinical score for all animals in a particular treatment
group or as the relapse rate (total number of relapses in a group
divided by the total number of mice in that group). A relapse
was defined as a sustained increase of at least one full grade in
clinical score after the animal had previously improved at least
a full clinical score and had stabilized. Scores of asymptomatic
mice (score = 0) were included in the calculation of the daily
mean clinical score for each group.
Histology. Anesthetized mice were sacrificed by total body perfusion with chilled 3% glutaraldehyde in PBS, pH 7.3. Spinal
cords were removed by dissection, cut into 1-mm-thick coronal
segments, postfixed in 1% osmium tetroxide, dehydrated, and
embedded in Epon as described previously (27). Toluidine
blue–stained sections from 10 segments per mouse were read
blindly and scored as follows: ±, mild inflammation without
demyelination; 1+, inflammation with focal demyelination; 2+,
inflammation with multiple foci of demyelination; 3+, marked
inflammation with bilateral, converging areas of demyelination;
4+, extensive bilateral areas of demyelination and remyelination.
Delayed-type hypersensitivity responses. Delayed-type hypersensitivity (DTH) responses to PLP139-151 and to PLP178-191 were
quantitated using a 24-h ear-swelling assay either directly after
the acute phase of disease or during remission. Pre-challenge
ear thickness was determined using a Mitutoyo model 7326
engineer’s micrometer (Schlesinger’s Tools, Brooklyn, New
York, USA). DTH responses were elicited by injecting 10 µg of
peptide (in 10 µl of saline) into the dorsal surface of the ear
using a 100-µl Hamilton syringe fitted with a 30-gauge needle.
Twenty-four hours after ear challenge, the increase in ear thickness over pre-challenge measurements was determined. Results
are expressed in units of 10–4 in. ± SEM.
In vitro T-cell proliferation assays. Spleen and lymph node cells
were obtained from mice at various stages of disease progression, and dissociated cells were cultured in 96-well microtiter
plates (Corning-Costar Corp., Acton, Massachusetts, USA) at
a density of 5 × 105 viable cells per well in a total volume of 200
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Figure 1
Anti-CD154 inhibits clinical progression of
established R-EAE. Mice were primed with
PLP139-151/CFA as described in Methods.
Mice were treated with either anti-CD154 or
control hamster IgG at time of priming (a), at
the peak of acute disease (b) (square symbols), or
during the remission following recovery from
acute disease (b) (triangular symbols). The data
are expressed as the mean clinical score versus
days after immunization for mice treated at the
time of immunization (a), or as relapse rate for
those mice treated during ongoing disease (b).
Data shown are representative of two similar
experiments. Ab, antibody; R-EAE, relapsing
experimental autoimmune encephalomyelitis.

µl DME or RPMI-1640 (Sigma Chemical Co.) supplemented
with 10% FCS (Sigma Chemical Co.), 100 U/ml penicillin (Life
Technologies Inc., Gaithersburg, Maryland, USA), 100 µg/ml
streptomycin (Life Technologies Inc.), and 2 mM L-glutamine
(Life Technologies Inc.). Cells were cultured at 37°C in 100%
humidity and 5% CO2 in the presence or absence (background)
of varying concentrations of either PLP139-151 or PLP178-191.
As a control, concanavalin A (Sigma Chemical Co.) was used at
a concentration of 5 µg/ml. Cultures were pulsed with 1 µCi of
3H-TdR (ICN Radiochemicals Inc., Irvine, California, USA) after
72 h, harvested at 96 h, and 3H-TdR uptake was detected using
a Packard Topcount microplate scintillation counter (Packard
Instrument Co., Meriden, Connecticut, USA). Results are
expressed as mean of triplicate cultures ± SEM.
Cytokine analysis. Draining lymph nodes (axillary and
inguinal) and spleen cells from mice primed with PLP139151/CFA were removed on day 10. A total of 200,000 cells/well
were plated onto 96-well flat-bottom plates in supplemented
DMEM and a range of PLP139-151 antigen concentrations.
Supernatants were harvested on days 1–4 and analyzed for IL2, IL-4, IL-5, IL-10, and interferon (IFN)-γ by capture ELISA.
ELISA reagents were purchased from Endogen Inc. (Woburn,
Massachusetts, USA) and were used according to the manufacturer’s protocol. Briefly, 96-well Nunc Maxisorb plates were
coated overnight with anti-cytokine capture antibody followed
by washing. Cytokine standards and samples were added to
coated wells and were incubated at 20°C overnight and washed.
Biotinylated anti-cytokine antibody was added, followed by
washing and the addition of Streptavidin-HRP conjugate.
DACO TMB (DAKO Corp., Carpinteria, California, USA) liquid substrate system was used. The plates were read at 450 nm.
Statistical analyses. Comparison of the percentage of animals
showing clinical disease and/or relapses between any two groups
of mice were analyzed by χ2 using Fisher’s exact test. Comparisons of DTH responses and lymphoid cell recoveries were analyzed by Student’s t test. P < 0.05 was considered significant.

Results
Anti-CD154 therapy inhibits clinical progression of established REAE. Previous studies have indicated that CD40–CD154
interactions are important for the development of acute
EAE in mice, because disease is blocked in either CD154deficient mice (14) or mice treated with anti-CD154 monThe Journal of Clinical Investigation
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oclonal antibody (MAB) at the time of disease initiation
(15). We wanted to confirm these results and to investigate
the more clinically relevant ability of anti-CD154 MAB
therapy to treat ongoing R-EAE. In accordance with previous findings, anti-CD154 administered during at the time
of PLP139-151 priming totally inhibited the development
of acute disease (Fig. 1a). Delay of treatment until mice
reached the peak of acute disease resulted in a marked
reduction in the relapse rate, with fewer mice exhibiting
clinical signs of relapse in the CD154-treated group compared with the controls (3/10 [30%] relapses vs. 10/10
[100%] in control mice; P < 0.01) and a delay in onset of
relapse for those mice exhibiting clinical signs (Fig. 1b). In
addition, relapses were short-lived in CD154-treated mice
compared with control mice, most of which relapsed more
than once during the observation period. The mean clinical disease score for relapsing mice (excluding mice that did
not relapse) was also markedly lower for the antiCD154–treated group (0.7 ± 0.6) compared with the control group (1.8 ± 0.7). The acute-phase disease profile was
identical in each treatment group. In each group, 10 of 10
mice developed acute clinical disease, with onset at day 12
and disease peak on day 16 (mean clinical scores: 2.2 ± 0.9
for control group and 2.2 ± 0.6 for CD154-treated mice).
Delay of treatment until mice reached remission was
nearly as effective as when treatment was initiated at the
peak of acute phase (Fig. 1b). The relapse rate for antiCD154–treated mice was significantly reduced compared
with that for control mice (7/19 [37%] relapses vs. 13/16
[81%] in control mice; P < 0.02). Again, onset of relapses was
delayed in anti-CD154–treated mice, and disease severity of
mice that relapsed in the treated group was markedly lower
than that of their controls. Collectively, these results indicated that anti-CD154 therapy provides a highly effective
way of treating ongoing R-EAE when administered either
at the peak of acute disease or during early remission.
Diminished CNS infiltration of immune cells and demyelinating
lesions in mice treated with anti-CD154 during ongoing disease.
Histologic examination of spinal cord sections was carried
out to determine whether the diminished clinical disease
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in anti-CD154–treated mice corre- Table 1
lated with reduced CNS infiltration Summary of histology in control and anti-CD154–treated mice
and demyelination. Antibody treatHamster Ig controls
Anti-CD154–treated
ment at the time of priming preTime of
Experiment Disease scoreB Histopathology
Disease score
Histopathology
vented the appearance of infiltrates treatmentA
number
(acute/relapse)
scoreC
(acute/relapse)
score
and demyelination in the spinal
1A
2/–
+
0/–
–
cords of mice examined after recov- Priming
1B
2/–
++
0/–
–
ery from acute disease (compare Fig.
2A
2/–
+
0/–
–
2, b with a). Spinal cords from con2B
4/–
++
0/–
–
trol Ig-treated mice that had under1A
2/2
++
2/0
–
gone at least one disease relapse Peak acute
1B
4/2
+++
4/0
–
exhibited markedly more extensive
2A
2/3
++
2/0
+/–
infiltrates and extensive demyelina2B
3/2
++
2/0
+/–
tion accompanied by glial scarring
when compared with mice examined ALumbar spinal cord sections from mice treated at the time or priming or at the peak of acute disease were
after the acute phase of disease (com- assessed for CNS histopathologic changes as detailed in the legend for Fig. 2. BPeak disease score from acute
relapsing (when relevant) phases of disease for the individual mice in each experiment. C Ten sections were
pare Fig. 2, c with a). In contrast, and
examined for each mouse and scored for disease on the following scale: –, no disease; +/–, meningitis; +, focal
mice treated with anti-CD154 at the infiltration and demyelination; ++, multiple infiltrates and demyelination; +++, confluent infiltrates and
peak of acute disease showed few demyelination. CNS, central nervous system.
immune cell infiltrates, little or no
demyelination, and no scarring (Fig.
2d). A semiquantitative comparison of the histology is topes by DTH, T-cell proliferation, and cytokine producsummarized in Table 1. There were few immune cell infil- tion assays. DTH responses measured during remission in
trates into the CNS of anti-CD154–treated mice, whether mice treated either at the time of inoculation or at the
treatment was initiated at the time of priming or at the peak of acute disease are shown in Fig. 3. DTH responses
peak of the acute phase of disease. This suggests that anti- to the PLP139-151 priming epitope were significantly
CD154 may act in part by either preventing activated reduced in the group treated with anti-CD154 at disease
myelin-specific T cells and/or macrophages from entering initiation compared with those of hamster Ig–treated conthe CNS or from being retained in the target organ.
trols (Fig. 3a, left; P < 0.05). Hamster Ig–treated controls
Myelin-specific DTH reactivity in anti-CD154–treated mice. demonstrated a significant DTH response to the relapseTo gain an understanding of the mechanisms by which associated PLP178-191 epitope, but anti-CD154–treated
anti-CD154 therapy led to amelioration of ongoing dis- mice exhibited no significant response (Fig. 3a, right). A
ease, we assessed T-cell responses to both the initiating similar pattern was observed in mice treated at the peak of
PLP139-151 and the relapse-associated PLP178-191 epi- acute disease in that anti-CD154 treatment significantly

Figure 2
Effect of anti-CD154 treatment on CNS histology. Lumbar spinal cord sections from representative animals of the treatment groups described in Fig.
1 were examined for CNS histopathology. (a) Section of spinal cord from a mouse treated with control Ig at the time of priming and sacrificed on
day 25. (b) Section of spinal cord from a mouse treated with anti-CD154 at the time of priming and sacrificed on day 25. (c) Section of spinal cord
from a mouse treated with control Ig at the peak of acute disease and sacrificed on day 40. (d) Section of spinal cord from a mouse treated with antiCD154 at the peak of acute disease and sacrificed on day 40. Details of the degree of inflammation and demyelination are given in Table 1. Sections
shown in a–d are 1-µm-thick Epon-embedded sections stained with toluidine blue. ×220. CNS, central nervous system.
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inhibited DTH to both the initiating (Fig. 3b, left) and
relapse-associated (Fig. 3b, right) epitopes. Thus, antiCD154 treatment of animals with ongoing R-EAE was significantly, but not totally, effective in inhibiting Th1
responsiveness and epitope spreading. This suggests that
anti-CD154 acts, at least in part, by inhibiting the effector
function of myelin-specific Th1 responses. Diminished in
vivo Th1 cell function could occur by either specifically
blocking expansion of myelin-specific Th1 responses
and/or by inhibiting Th1 differentiation.
Myelin-specific T cell–proliferative and cytokine responses in
anti-CD154–treated mice. To examine the potential effects
of anti-CD154 treatment on Th1 expansion and/or differentiation, we assessed the level of myelin-specific T-cell
proliferation and cytokine production in treated mice.
Anti-CD154 treatment led to a 60% reduction in recovery
of lymph node lymphocytes, but not splenic lymphocytes, in mice treated at the time of priming (Fig. 4; P <
0.05). A similar reduction in lymph node cell numbers
was seen in mice treated at peak of acute phase when cell
numbers were assessed 10 days later (data not shown).
The decreased recovery of lymph node lymphocytes in
mice treated with anti-CD154 during priming was paralleled by a significant decrease in lymph node T cell–proliferative responses to the inducing PLP139-151 epitope
when compared with controls (Fig. 4a). However, the
splenic T cell–proliferative response to PLP139-151 was
significantly higher in anti-CD154–treated mice 10 days
after priming. No significant responses to the relapseassociated PLP178-191 epitope were observed in the
lymph nodes or spleens of either control or antiCD154–treated mice (Fig. 4b), which is to be expected, as
these animals had not yet undergone acute disease. A similar pattern of results was observed in mice treated at peak
of acute disease. PLP139-151–specific proliferative
responses of lymph node cells harvested when the mice
reached remission (day 25 after immunization) was also
significantly diminished in anti-CD154–treated mice
compared with controls (Fig. 4c), whereas splenic
responses were not suppressed. Noticeably, in both cases,
levels of PLP139-151–specific proliferation of splenic and
lymph node cells were reduced compared with the levels
observed on day 10 after immunization (Fig. 4a). During
remission, significant dose-dependent proliferative
responses to the relapse-associated PLP178-191 epitope
were observed in both spleen and lymph node cells of
control mice (Fig. 4d). PLP178-191–specific responses
were markedly reduced in the lymph nodes and increased
in the spleens of anti-CD154–treated mice compared
with controls. Because lymph node cell recovery was significantly lower from anti-CD154–treated compared with
control mice, the diminished proliferative responses to
both epitopes observed in this population could have
been due to diminished numbers of T cells. This is unlikely, however, because concanavalin A–induced proliferation of lymph node T cells was comparable in antiCD154–treated and control mice (data not shown).
Collectively, although myelin epitope–specific T-cell proliferative responses were reduced in the lymph nodes of
antibody-treated mice, the degree of suppression is
unlikely to account for the very marked effects of antiCD154 on clinical disease in light of the enhanced
The Journal of Clinical Investigation

|

Figure 3
Anti-CD154 treatment inhibits DTH responses to both the initiating and
relapse-associated myelin epitopes. DTH responses to both the initiating
PLP139-151 peptide and to the relapse-associated PLP178-191 peptide
were evaluated in mice treated with either control Ig or anti-CD154 at the
time of priming (a) or at the peak of acute disease (b). Data represent
mean ± SD of the change in ear thickness 24 h after ear challenge with 10
µg of peptide. The numbers of mice in each group are shown below each
bar. Data are representative of two experiments with similar results. DTH
responses significantly less than those of control Ig-treated mice: *P <
0.05; **P < 0.01). Results shown above each bar show statistical comparisons to background ear-swelling levels, i.e., levels in naive mice challenged with each peptide. DTH, delayed-type hypersensitivity.

responses observed in the splenic T-cell compartment.
Anti-CD154 treatment blocks the differentiation of PLP139151–specific Th1 cells. The proliferative data suggest that
anti-CD154 may partially interfere with the clonal
expansion of PLP-specific T cells. To determine the
effects of anti-CD154 treatment on Th1 differentiation,
we assessed the ability of PLP-responsive T cells to produce both Th1 (IFN-γ and IL-2)- and Th2 (IL-4, IL-5, and
IL-10)-type cytokines. Secondary in vitro stimulation of
PLP139-151–specific T cells, derived from the spleens of
mice treated with anti-CD154 at time of priming,
demonstrated control levels of IL-2 production (Fig. 5a);
however, IFN-γ production was almost completely suppressed (Fig. 5c). Lymph node–derived cells also exhibited significantly reduced levels of IFN-γ production (Fig.
5d); however, unlike splenic T cells, IL-2 production was
also somewhat reduced (Fig. 5b). PLP139-151–induced
IL-4 and IL-5 production was also assessed, but only
minimal levels of secretion of these cytokines were
observed in all cultures (data not shown). Similarly, low,
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Figure 4
Myelin epitope-specific in vitro proliferative responses of spleen and lymph node cells from mice treated with anti-CD154 during disease induction or
at the peak of acute disease. Splenic and lymph node lymphocytes from three mice each treated with control Ig or anti-CD154 either at the time of
priming were harvested at day 10 after immunization (a and b) or at the peak of acute disease were harvested at day 25 after immunization (c and
d). A total of 5 × 105 viable cells per well were cultured with varying concentrations of PLP139-151 or PLP178-191 for 4 days. Cultures were pulsed
with 3H-TdR 18–24 h before harvest. Data are presented as ∆CPM (3H-TdR incorporation in cultures containing peptide antigen – 3H-TdR incorporation in cultures containing medium). Data shown are representative of two experiments. Mean ± SD of viable lymphocytes recovered from each
treatment group (minimum of three mice each from three separate experiments) is shown in the legend ( *P < 0.05). Stimulation indices (S.I.) are
shown for each treatment group at the concentration of peptide that stimulated optimal proliferation. An S.I. ≥3 is considered significant.

but comparable, levels of IL-10 secretion were observed
in both control and anti-CD154–treated mice (Fig. 5, e
and f). The lack of IFN-γ production by splenic T cells
from anti-CD154–treated mice is particularly remarkable, because this population exhibited enhanced proliferative capacity (Fig. 4a) and produced control levels of
IL-2 (Fig. 5a). These results are consistent with the ability of anti-CD154 to inhibit Th1 differentiation in other
autoimmune models (17, 20, 28), as well as in models of
graft-versus-host disease and graft rejection (29, 30) and
with our observation that anti-CD154 treatment significantly inhibited development of DTH responses (Fig. 3).
Anti-CD154 treatment of donor mice inhibits the generation of
encephalitogenic T cells. To gain further understanding of
how anti-CD154 treatment prevents EAE, the effect of
anti-CD154 treatment on adoptive R-EAE was studied.
SJL/J mice were immunized with PLP139-151/CFA and
treated with anti-CD154 or hamster Ig on days 0, 2, 4, and
6. On day 8, the draining lymph nodes were removed and
activated in vitro with PLP139-151 for four days, and varying numbers of viable cells (2.5 × 106 –107) were adoptively transferred into naive SJL/J recipients. Treatment of
286

The Journal of Clinical Investigation

|

donor mice with anti-CD154 reduced the capacity of
PLP139-151–specific T cells to transfer disease as judged
by a reduction in disease severity and/or onset. Inhibition
was most evident when limiting numbers of donor cells
(2.5 × 106 to 5 × 106 cells/mouse; Fig. 6, b and c) from antiCD154–treated mice were transferred. Inclusion of antiCD154 during the in vitro culture only did not decrease the
encephalitogenicity of the donor T cells (Fig. 6b). However, complete blockade of disease transfer was observed
when the donor T cells were derived from mice treated
with anti-CD154 and α-CD154 was included during the
in vitro activation culture and cells transferred to antiCD154–treated recipients. Therefore, anti-CD154 treatment blocks the generation of encephalitogenic T cells
consistent with its suppressive effects on development of
clinical disease (Fig. 1) and differentiation of myelin epitope-specific Th1 cells (Figs. 3 and 5).
Anti-CD154 treatment of recipients reduces the onset and severity of R-EAE. The fact that treatment of mice at the peak of
acute disease or during remission ameliorated relapsing
disease suggests that anti-CD154 can interfere with disease
development even after the expansion and differentiation
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of encephalitogenic T cells. To assess directly the effects of
anti-CD154 on the effector phase of disease, graded numbers (1.25 × 106 to 5 × 106) of PLP139-151–primed T cells
were adoptively transferred into naive recipients who were
subsequently treated with anti-CD154 or control Ig. AntiCD154 treatment significantly reduced disease severity
even upon the transfer of the highest numbers of primed
T cells (Fig. 7a; 5 × 106/mouse). More profound inhibition
of disease transfer was observed in treated recipients receiving lower numbers of transferred cells (Fig. 7, b and c).
Blockade of encephalitogenic T-cell function may be due
to either interference with CNS homing of the activated
encephalitogenic T cells or direct interference with other
effector functions (i.e., the ability to produce/secrete proinflammatory cytokines), or both.

Discussion
CD40–CD40L (CD154) interaction plays multiple important roles in regulating both humoral and cell-mediated
immune responses. Significant to its potential as an
immunotherapeutic agent for the treatment of autoimmune diseases, anti-CD154 has been shown previously to
block the spontaneous development of pathogenic
autoantibodies in lupus-prone mice (18, 31) and to inhibit the induction of experimental collagen-induced arthritis (19) and trinitrobenzene sulphonic acid (TNBS)induced colitis (28). CD40–CD40L interactions have also
been implicated in the induction of R-EAE. CD154
knockout mice, expressing an MBP-specific transgenic
TCR, fail to develop clinical disease (14), and antibody to
CD154 has been shown to inhibit EAE induction (15).
At present, there is little information on the mechanism(s) whereby anti-CD154 inhibits EAE induction,
and none on its therapeutic potential for treating ongoing T cell–mediated autoimmune diseases such as REAE. Such knowledge is extremely relevant to the potential application of this therapy in human multiple
sclerosis and other autoimmune diseases. In this article,
we address both of these questions and show that
CD40/CD154 interactions are critical for both the initiation and progression of R-EAE. Anti-CD154 treatment
effectively inhibits R-EAE when administered both at
time of disease induction, confirming earlier studies
(15), and, more importantly, during ongoing R-EAE. In
addition, we show that anti-CD154–induced inhibition
of clinical disease is associated with differential regulation of lymph node and splenic responses to self myelin
peptides, resulting in reduced activation of Th1-type
responses and inhibition of the effector function of differentiated encephalitogenic T cells.
Treatment of ongoing R-EAE with anti-CD154 was
more or less equally effective when given either early (at
peak of acute disease) or later when mice were in remission following the acute disease incident (Fig. 1b). Treatment resulted in a significant reduction in the percentage of animals displaying disease relapses and a delay in
the onset and clinical severity in those mice that did
relapse. Treatment at either time during ongoing disease
also resulted in a profound reduction of inflammation
and demyelination in the CNS (Fig. 2). The ameliorating
effects of anti-CD154 therapy could occur at multiple
levels. Relapses in PLP139-151–induced R-EAE in the SJL
The Journal of Clinical Investigation
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Figure 5
Anti-CD154 treatment blocks the differentiation of PLP139-151-specific,
IFN-γ–producing Th1 cells. Splenic and lymph node lymphocytes from
three mice each treated at time of priming with either control Ig or antiCD154 were harvested at day 10 after immunization. A total of 2 × 105
viable cells/well were cultured with an optimal dose of PLP139-151 (25
µM). Culture supernatants were harvested each day and analyzed for IL2, IFN-γ, and IL-10 by ELISA, as described in Methods. Data shown are
representative of two experiments. In all cases, the SD was less than 10%
of the values. IFN, interferon; IL, interleukin.

mouse are mediated largely by epitope spreading (4),
wherein T cells specific for the endogenous PLP178 epitope are primed de novo in response to myelin damage
mediated by T cells specific for the initiating epitope.
Thus, anti-CD154 may act in part by inhibiting the
expansion and/or differentiation of Th1 cells specific for
relapse-associated epitopes. Blockade of CD40/CD154
interactions could also directly interfere with the effector functions of differentiated Th1 effector cells. This
could occur via direct effects on the production of proinflammatory cytokines or by interfering with the ability
of encephalitogenic T cells to transmigrate into the CNS
and/or recruit and activate macrophages. In contrast to
R-EAE, in the NOD mouse, CD40/CD154 blockade
inhibits development of diabetes only when administered to young mice (4 weeks of age), but not in older
mice (9–10 weeks of age), when significant autoimmune
disease has already developed (20). This may reflect the
difference in a chronic progressive diabetes model versus
the relapsing EAE model, perhaps associated with the
transient nature of CD40/CD154 interaction in initiating responses to relapse-associated epitopes.

January 1999

|

Volume 103

|

Number 2

287

The possibility that anti-CD154 may directly block
transmigration of encephalitogenic T cells across the
blood–brain barrier is suggested by the fact that adoptive transfer of R-EAE was significantly, but not completely, inhibited by anti-CD154 treatment of recipients
of activated PLP139-151–specific T cells (Figs. 6 and 7).
CD40 ligation has been shown to activate endothelial
cells upregulating expression of adhesion molecules (32)
and production of proinflammatory cytokines (33) that
can promote extravasation of lymphocytes. Although
human endothelial cells have been shown to express
functional CD40 (24, 32), our preliminary experiments
examining CD40 and CD40L expression on mouse cerebrovascular endothelial cells (CVEs) in vivo and on
cloned CVEs in vitro have failed to detect significant

Figure 6
Anti-CD154 treatment of donor mice diminishes the capacity of PLP139151–primed T cells to transfer R-EAE. Female SJL/J mice were primed with
PLP139-151/CFA. These donor mice treated with either 250 µg of control Ig (open squares) or anti-CD154 (closed squares) on days 0, 2, 4, and 6.
Draining lymph nodes were harvested on day 8 and cultured with 70
µg/ml PLP139-151 in vitro. After 4 days in culture, naive female SJL/J
recipient mice were injected intravenously with 107 (a), 5 × 106 (b), or 2.5
× 106 (c) viable cells. In b, some mice received cells from antiCD154–treated donors that were also treated with 25 µg/ml of antiCD154 in vitro (open triangles). In addition, some mice received cells from
anti-CD154–treated donors that were exposed to anti-CD154 during the
in vitro activation culture and transferred into anti-CD154 treated recipients (closed triangles). Recipients treated with anti-CD154 were injected
with 250 µg intraperitoneally three times a week. Mice were examined for
disease severity and scored as described in Methods.
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expression of either molecule (Gordon, K.B., et al., manuscript in preparation). Thus, it appears unlikely that
anti-CD154 directly obstructed T-cell migration into the
CNS by blocking T cell–endothelial cell interactions, but
we are continuing to examine this possibility using cell
tracking studies employing the transfer of encephalitogenic T cells from SJL Thy1.1–congenic mice into naive
SJL Thy1.2–bearing recipients. The in vivo effect on adoptive R-EAE more likely lies in the inhibition of T cell/APC
interactions in the CNS of the recipient animal resulting
in the downregulation of effector inflammatory responses. This could occur by blocking delivery of costimulatory signals to the encephalitogenic T cells required for
production of chemokines and/or proinflammatory
cytokines, and/or by inhibiting CD40 signaling of CNSresident macrophages/microglia and astrocytes, preventing the production of inflammatory mediators, e.g.,
NO and matrix metalloproteinases (34–36).
Regarding the ability of anti-CD154 therapy to prevent
the expansion and/or differentiation of myelin epitope–specific T cells, our results suggest that its major
effect lies at the level of inhibiting the differentiation of
Th1 cells specific for both the initiating and relapse-associated myelin epitopes. Using thymidine incorporation in
both the spleens and draining lymph nodes of PLP139151–primed mice as a measure of T-cell expansion, our
results suggest that the effects of anti-CD154 treatment
were minimal. We observed an interesting dichotomy in
that the lymphoid cell numbers and myelin epitope–specific proliferative responses were significantly diminished
in the lymph nodes of anti-CD154–treated mice, but this
was apparently balanced by a concomitant increase in
splenic T-cell responses (Figs. 4 and 5). One possible
explanation may lie in the fact that splenic APCs from
autoimmune-prone SJL mice express higher constitutive
levels of cell surface expression of CD80/CD86 costimulatory molecules than do lymph node APCs (37) and may
thus be less sensitive to the inhibitory effects of antiCD154 on CD40-mediated upregulation of CD80/CD86
(14, 24, 25, 38, 39) and IL-12 (26, 28, 40, 41) in APCs.
Other recent studies have observed a similar reduction of
T-cell expansion by anti-CD154 in the lymph nodes in a
TCR transgenic mouse system (42), as well as in other
EAE-susceptible mice (43), supporting the observations
in this study. The differential effects on antigen-specific
proliferative responses in the lymph nodes versus spleens
of anti-CD154–treated mice may thus reflect diminished
priming of T-cell precursors in the lymph node; migration of the precursor cells to the spleen, where they may
become activated; and/or a switch to Th2-type response,
through inhibition of IL-12 production by absence of
CD40 ligation on the APCs. However, it should be noted
that the latter possibility is apparently not supported by
our failure to demonstrate IL-4, IL-5, or increased IL-10
production by either splenic or lymph node T cells from
anti-CD154–treated mice (Fig. 6). Alternatively, the
reduced lymph node response observed in antiCD154–treated mice may reflect a disruption of the
architecture of the lymph nodes preventing efficient Tcell expansion or retention.
Separate from its potential effects on T-cell expansion,
the net result of anti-CD154 treatment is clearly a reduc-
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tion in Th1 differentiation and effector function. This is
suggested by a number of pieces of experimental data.
First, DTH responsiveness, a measure of in vivo generation of Th1 cells (44), to both the initiating and relapseassociated PLP epitopes is significantly reduced in antiCD154–treated mice (Fig. 3). Second, while in vitro
production of IL-2 by myelin-specific T cells was largely
unaffected, we observed dramatically reduced levels of
IFN-γ production (reflecting diminished Th1 responses)
by both lymph node and splenic T cells (Fig. 6), also suggesting that anti-CD154 blocked T-cell Th1 differentiation. This pattern of cytokine production suggests that
T cells expanded in anti-CD154–treated mice possessed
Th0 characteristics. Third, our results indicate that
expansion of PLP139-151–specific encephalitogenic T
cells in anti-CD154–treated donors was decreased in that
these cells were less effective in transferring disease to
naive SJL recipients (Fig. 7). By all of these criteria, antiCD154 therapy appears to have a major downregulatory
effect on Th1 differentiation. Given that effective inhibition of disease transfer only occurred when recipient
mice were also treated, it appears that anti-CD154 not
only inhibits differentiation of encephalitogenic Th1
cells but may also interfere with their homing and/or
effector functions as already discussed here.
In summary, these results verify the immunotherapeutic potential of anti-CD154 for treatment of established T cell–mediated autoimmune diseases. Experiments addressing the mechanisms accounting for the
amelioration of ongoing R-EAE indicate a profound
effect of CD40–CD154 blockade on the differentiation
and effector functions of autospecific Th1 cells. Further
characterization of lymph node and splenic cell populations in anti-CD154–treated mice should provide significant information as to the exact molecular events
involved in disease regulation.
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